CURE.AX vs. GXLD.AX
CURE.AX (Global X S&P Biotech ETF) and GXLD.AX (Global X Gold Bullion ETF) are both exchange-traded funds - CURE.AX is a Health & Biotech Equities fund tracking the S&P Biotechnology Select Industry Index, while GXLD.AX is a Gold fund tracking the Global X Gold Bullion Index. Both are passively managed. Over the past year, CURE.AX returned 65.69% vs 11.59% for GXLD.AX. At a 0.01 correlation, their price movements are largely independent.
Performance
CURE.AX vs. GXLD.AX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CURE.AX achieves a 22.66% return, which is significantly higher than GXLD.AX's -11.66% return.
CURE.AX
- 1D
- 0.58%
- 1M
- 17.05%
- 6M
- 20.39%
- YTD
- 22.66%
- 1Y
- 65.69%
- 3Y*
- 21.60%
- 5Y*
- 5.62%
- 10Y*
- —
GXLD.AX
- 1D
- -0.17%
- 1M
- -5.54%
- 6M
- -17.02%
- YTD
- -11.66%
- 1Y
- 11.59%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
CURE.AX vs. GXLD.AX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
CURE.AX Global X S&P Biotech ETF | 22.66% | 25.25% | 11.14% |
GXLD.AX Global X Gold Bullion ETF | -11.66% | 54.77% | 17.24% |
Correlation
The correlation between CURE.AX and GXLD.AX is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.08 |
Correlation (All Time) Calculated using the full available price history since May 2, 2024 | 0.01 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CURE.AX vs. GXLD.AX — Risk / Return Rank
CURE.AX
GXLD.AX
CURE.AX vs. GXLD.AX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Global X S&P Biotech ETF (CURE.AX) and Global X Gold Bullion ETF (GXLD.AX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CURE.AX | GXLD.AX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.15 | ||
| Sortino ratioReturn per unit of downside risk | +2.66 | ||
| Omega ratioGain probability vs. loss probability | 1.43 | 1.11 | +0.31 |
| Calmar ratioReturn relative to maximum drawdown | 5.80 | 0.47 | +5.32 |
| Martin ratioReturn relative to average drawdown | 14.61 | 1.08 | +13.53 |
Loading charts...
Drawdowns
CURE.AX vs. GXLD.AX - Drawdown Comparison
The maximum CURE.AX drawdown since its inception was -59.81%, which is greater than GXLD.AX's maximum drawdown of -24.63%. Use the drawdown chart below to compare losses from any high point for CURE.AX and GXLD.AX.
Loading charts...
Drawdown Indicators
| CURE.AX | GXLD.AX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -59.81% | -24.63% | -35.18% |
Max Drawdown (1Y)Largest decline over 1 year | -11.68% | -24.63% | +12.95% |
Max Drawdown (3Y)Largest decline over 3 years | -28.37% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -50.92% | — | — |
Current DrawdownCurrent decline from peak | -5.45% | -24.63% | +19.18% |
Average DrawdownAverage peak-to-trough decline | -27.38% | -5.14% | -22.24% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.66% | 10.98% | -6.32% |
Volatility
CURE.AX vs. GXLD.AX - Volatility Comparison
Global X S&P Biotech ETF (CURE.AX) has a higher volatility of 9.67% compared to Global X Gold Bullion ETF (GXLD.AX) at 6.13%. This indicates that CURE.AX's price experiences larger fluctuations and is considered to be riskier than GXLD.AX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CURE.AX | GXLD.AX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.67% | 6.13% | +3.54% |
Volatility (6M)Calculated over the trailing 6-month period | 21.01% | 20.99% | +0.02% |
Volatility (1Y)Calculated over the trailing 1-year period | 25.95% | 24.56% | +1.39% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 30.91% | 20.45% | +10.46% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 31.70% | 20.45% | +11.25% |
Dividends
CURE.AX vs. GXLD.AX - Dividend Comparison
Neither CURE.AX nor GXLD.AX has paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
CURE.AX Global X S&P Biotech ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.06% | 11.64% | 9.47% | 2.05% |
GXLD.AX Global X Gold Bullion ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
CURE.AX and GXLD.AX have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CURE.AX is categorized as Health & Biotech Equities, while GXLD.AX is Gold. CURE.AX tracks S&P Biotechnology Select Industry Index, while GXLD.AX tracks Global X Gold Bullion Index.
Find the right allocation for CURE.AX and GXLD.AX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer